SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3052More of the same from SITC2014.... immunotherapyofcancer.orgscaram(o)uche-11/6/2014
3051>> 986 is gone from the pipeline chart << j l ?@lomu_j21m21 minutesscaram(o)uche-10/30/2014
3050updated..... GILD - Idelalisib, GS-9901 (GS-9901 not confirmed PI3Kdelta, but lscaram(o)uche-10/29/2014
3049Fun (and probably useless) factoid..... Dr. Khleif is also P.I. at the only siscaram(o)uche-10/24/2014
3048Interesting. Don't think I ever put this abstract up, as it didn't honescaram(o)uche-10/23/2014
3047Wo! finance.yahoo.com NewLink Genetics Announces Exclusive Worldwide Licensingscaram(o)uche-10/20/2014
3046Updated...... Tuck has found another clinical-stage project from Rhizen. GILD scaram(o)uche-10/19/2014
3045Was NOT expecting this..... clinicaltrials.govscaram(o)uche-10/17/2014
3044Talked about panabinostat, and results showing recovery of marrow. Now therescaram(o)uche-10/17/2014
3043986 is gone from the pipeline chart? Stepping in is 793 (no detail beyond "scaram(o)uche-10/16/2014
3042>> Relative Bioavailability of the Baricitinib (LY3009104) Commercial Tablscaram(o)uche-10/14/2014
3041PLoS One. 2014 Oct 7;9(10):e109799. doi: 10.1371/journal.pone.0109799. eCollectiscaram(o)uche-10/8/2014
3040Housekeeping note...... Xeljanz did $68m in 2nd quarter. Psoriasis trial coscaram(o)uche-10/8/2014
3039Yes. It promptly went to $70.scaram(o)uche-10/7/2014
3038cool..... news.bms.com Bristol-Myers Squibb Announces Collaboration to Evaluatscaram(o)uche-10/6/2014
3037Looked like a dedicated seller ("capping") yesterday, on relatively hiscaram(o)uche-10/3/2014
3036<i>Incyte will record this amount as contract revenue in the third quarterscaram(o)uche-10/2/2014
3035Interesting trial...... clinicaltrials.gov nilotinib plus rux, Novartis trial,scaram(o)uche-10/2/2014
3034It's only been two years? Sheesh, seems like forever. RA-BEAM fully enrollscaram(o)uche-9/29/2014
3033GILD - Idelalisib INCY - INCB40093 TGTX - TGR-1202 INFI - IPI-145 and IPI-443 scaram(o)uche-9/17/2014
3032BRUSSELS, Aug 8 (Reuters) - Belgian biotech group Galapagos said its partner Glanigel bates-8/8/2014
3031I did substantially increase my GILD position, but lost out on INCY and TGTX, a Biotech Jim-6/18/2014
3030This list back in play? Wouldn't it be surprising if GILD ended up in the cscaram(o)uche-6/16/2014
3029NEW YORK & WILMINGTON, Del.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company nigel bates-5/27/2014
3028"c-reactive proteins levels greater than 13 mg/dl" thestreet.comscaram(o)uche-5/14/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News